(University of California - San Francisco) An experimental drug called Ocrelizumab has shown promise in a phase two clinical trial involving 220 people with multiple sclerosis, an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
It usually strikes young adults and is more common in women than in men.